Trial Profile
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs MK 2206 (Primary) ; Everolimus
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 03 Jan 2017 Results of futility analysis (n=43), published in the Annals of Oncology
- 03 Jan 2017 Status changed from active, no longer recruiting to discontinued, as the trial met the futility criteria at the planned interim analysis, according to the results published in the Annals of Oncology
- 19 Nov 2015 Planned number of patients changed from 105 to 114 as reported by ClinicalTrials.gov record.